Table of Contents
- Definition of Aplastic Anemia
- Epidemiology of Aplastic Anemia
- Etiology of Aplastic Anemia
- Classification of Aplastic Anemia
- Pathophysiology of Aplastic Anemia
- Clinical Features of Aplastic Anemia
- Investigations of Aplastic Anemia
- Differential Diagnosis of Aplastic Anemia
- Management of Aplastic Anemia
- Complications of Aplastic Anemia
Definition of Aplastic Anemia
The world health organization (WHO) defines anemia as a blood hemoglobin level which is less than the reference lower limit for a specific age and sex. Aplastic anemia is a disorder characterized by pancytopenia and hypocellular bone marrow in the absence of infiltrative disease to the bone marrow.
The disorder should be distinguished from bone marrow failure which is characterized by pancytopenia in the presence of fibrosis, disordered cell maturation, myelodysplasia, and hyperplasia of the bone marrow. Peripheral cell count defines the severity of aplastic anemia counts as postulated by the international aplastic anemia study group (IAASG):
Moderate aplastic anemia
This includes decreased bone marrow cellularity with peripheral pancytopenia that does not meet the criteria for severe aplastic anemia.
Severe aplastic anemia (SAA)
Bone marrow cellularity < 25 %
Neutrophil count < 500 × 106 /L
Platelet count < 20,000 × 106 /L
Reticulocyte count3 < 60,000 × 106 /L
Very severe aplastic anemia (VSAA)
Neutrophil count is < 200 ×106 /L in a patient fulfilling the criteria for severe aplastic anemia.
Epidemiology of Aplastic Anemia
Aplastic anemia is a rare disease affecting 1 or 2 people per million each year in Europe.
There are 300—600 new cases reported in the United States each year. The disease has no sexual predilection and research suggests that it is more common among Asians compared to Europeans and Americans. The risk is postulated to increase with exposure to the causative toxins such as pesticides containing benzene and arsenic, chemotherapy, radiotherapy, and medications such as chloramphenicol.
Etiology of Aplastic Anemia
Aplastic anemia underlies a defect in bone marrow or stem cells leading to aplasia of different cell lines including red blood cells. Although pediatric aplastic anemia is sometimes idiopathic, there is a number of etiological factors known that causes aplastic anemia. It may be congenital or acquired, but, more than 80 % of the cases are of an acquired nature.
Causes of congenital/inherited aplastic anemia in children
Congenital causes constitute up to 25 % of the cases of aplastic anemia in children:
- Fanconi anemia
- Dyskeratosis congenital
- Familial aplastic anemia (mutations in TERC and TERT genes)
- Cartilage-hair hypoplasia (mutation in RMRP gene)
- Pearson syndrome
- Shwachman-Diamond syndrome (mutation in SBDS gene)
- Dubowitz syndrome
- Diamond-Blackfan anemia
Causes of acquired aplastic anemia in children
Most cases of aplastic anemia (up to 80 %) in children are due to acquired causes:
- Infections (hepatitis viruses, Epstein-Barr virus, and mycobacteria)
- Exposure to ionizing radiation
- Exposure to toxic chemicals (benzene or pesticides)
- Orthotopic liver transplantation for fulminant hepatitis
- Acute lymphoblastic leukemia (ALL)
- Certain drugs, such as chloramphenicol and phenylbutazone
Classification of Aplastic Anemia
Congenital/inherited aplastic anemia
- Major causes of inherited aplastic anemia presented as syndromes with/without distinctive physical features
- Fanconi anemia
- Dyskeratosis congenital
- Shwachman-Diamond syndrome
- Amegakaryocytic thrombocytopenia
Acquired aplastic anemia
Main causes of acquired aplastic anemia include:
- Viral infections, such as Epstein Barr Virus, Parvovirus B19, HIV and Cytomegalovirus
- Toxins such as benzene and gold
- Drugs such as chloramphenicol
- Radiotherapy and chemotherapy use in the treatment of cancers
Pathophysiology of Aplastic Anemia
Several pathways have been put forward to explain the pathophysiology of aplastic anemia. However, studies suggest that stem cell defect is the central mechanism of pathogenesis of the disease and every pathway involves this process. The undifferentiated cells in the bone marrow are damaged until the balance between self-renewal and differentiation into mature cells is lost.
The damage is characterized by the sparing of the bone marrow stroma, blood vessels and the replacement of damaged cells with fat cells; therefore, hematopoiesis progresses normally after stem cell transplant since the supportive stroma is intact.
The majority of acquired aplastic anemia in children are of unknown origin. The marrow is believed to be suppressed by IFN-ɤ whose gene is over-expressed in children with aplastic anemia. These patients respond to immunosuppressive therapy and stem cells transplantation.
This pathophysiology is thought to be the causative pathology of the majority of the acquired cases. In this pathway, suppression of hematopoiesis is thought to arise from an expansion of CD8 cytotoxic T lymphocytes that secrete inhibitory cytokines such as TNF-α and IFN-ɤ which inhibit the cell cycle and promote apoptosis.
Moreover, they produce cytotoxic nitric oxide that causes direct damage to the stem cells. The theory is supported by the identification of an increased population of cytotoxic lymphocytes in patients with aplastic anemia and their response to immunosuppressive therapy.
The use of drugs such as chloramphenicol and toxins such as benzene and gold leads to toxic damage of the stem cells causing pancytopenia. This idiosyncratic reaction is thought to arise from the difference in metabolism among individuals. The affected patients metabolize the precursors into more toxic products that destroy the bone marrow stem cells.
Toxic viruses such as HIV are associated with T cell activation and increase in cytokines that inhibit progenitor cell growth. Parvovirus B 19 is a common cause of aplastic anemia which selectively attacks proerythroblasts, resulting into red cell aplasia that worsens into pancytopenia, especially in immunocompromised patients.
Inherited aplastic anemia results from genetic mutations such as TERC and TERT in infantile aplastic anemia. Expression of these genes confers susceptibility to the damage of stem cells via immune mechanisms and thus leads to aplastic anemia. This type of disease commonly presents in association with other physical findings, such as short stature, organ defects involving the liver, kidneys and the heart and poorly pigmented hair.
After stem cells are damaged and production is compromised, the deficiency spills over into peripheral circulation to cause depletion of all cell lines, i.e., pancytopenia ensues leading to the clinical manifestations of the disease.
Clinical Features of Aplastic Anemia
These children present with symptoms of depressed cell lines, such as easy bruising and mucocutaneous bleeding due to thrombocytopenia, fatigue, palpitations, tachycardia, and headache due to low levels of red blood cells and recurrent infections due to the depletion of white blood cells.
Symptoms might be clearly apparent in the advanced stages of aplastic anemia. Common symptoms of aplastic anemia in children are:
- Shortness of breath
- Easy bruising
- Chest pain
- A history of past hospitalization due to infections
General signs are pallor due to ineffective erythropoiesis, fever due to infections resulting from neutropenia and a mucosal ulceration.
Cardiovascular signs tachycardia:
Children with congenital syndromes present with physical stigmata such as:
- Short stature with short limbs
- Renal, cardiac, and gastrointestinal (GI) abnormalities
- Sparse and lightly pigmented hair
- Dysplastic nails
- Oral leukoplakia
Neutropenia presented clinically as:
Neutropenia could mainly be described as recurrent bacterial infections that mostly affect the oral and pharyngeal mucosa and the patients present with mucosal ulcerations, fevers, and a history of past hospitalization due to the infections.
Low levels of red blood cells and hemoglobin presented as a headache, dizziness, palpitations, and fatigue, dyspnea, and chest pain.
Thrombocytopenia is mostly presented by easy bruising, nosebleeds, mucosal bleeding, gingival bleeding, petechial rashes, and purpura ecchymosis.
Investigations of Aplastic Anemia
The workup of these patients focuses on the establishment of the diagnosis and grading of the severity of the disease. Hemoglobin level estimation and a complete blood count are done to classify the severity of the disease, while bone marrow aspirate and biopsy is done to establish the diagnosis.
The following investigations are significant in making a diagnosis:
|Complete Blood Count (CBC)||
|Bone Marrow Aspirate||
|Bone Marrow Biopsy||
Differential Diagnosis of Aplastic Anemia
Differential diagnosis of aplastic anemia in children is required to be made under the following conditions:
- Bone marrow failure
- Myelodysplastic syndromes
- Paroxysmal nocturnal hemoglobinuria
- Inherited syndromes associated with bone marrow failure can be distinguished from aplastic anemia due to the presence of associated physical stigmata in the former
- Acute myeloid leukemia and acute lymphoblastic leukemia are considered in patients who present with features such as hepatomegaly or splenomegaly
- Non-Hodgkin’s lymphoma should be considered in patients with constitutional symptoms, hepatomegaly, and splenomegaly
- Multiple myelomas
Management of Aplastic Anemia
This helps to replenish lost blood and alleviate the suffering of the patient. Blood from family members is avoided during transfusions to avoid sensitization of blood from a potential stem cell donor. Infections are a major cause of mortality in these patients and broad-spectrum antibiotic coverage is employed. With neutropenic counts, they are susceptible to bacterial and fungal infections; thus, an antibiotic and antifungal agent is indicated in patients with a count of < 0.2 × 109 /l.
Immunosuppressive therapy (IST) is the most used therapy, especially in patients older than 40 years suffering from severe aplastic anemia (SAA), very severe aplastic anemia (VSAA) and non-severe aplastic anemia who are transfusion dependent.
The first line agents in use are anti-thymocyte globulin (ATG) at a dose of 40 mg/kg per day for four days and cyclosporine began on day five as divided doses amounting to 15 mg/kg/day until a response is achieved.
Hormonal/stimulant therapy has been tried and success reported in patients who are refractory to IST. Thrombopoietin receptor agonists such as eltrombopag, granulocyte stimulating factors such as filgrastim and granulocyte macrophage stimulating factors such as sargramostim, are administered to stimulate the stroma to encourage stem cell production and maturation.
Hematopoietic cell transplantation (HCT) is indicated in patients with less than 40 years of age and suffering from severe aplastic anemia (SAA) or very severe aplastic anemia (VSAA). The stem cells may be obtained from either A HLA matched and related donor or an HLA matched but unrelated donor. Another possibility would be cord blood in patients who lack an HLA match but have failed to respond to immunosuppressive therapy. It is the treatment of choice due to its high success rates.
Complications of Aplastic Anemia
If left untreated, the disease may progress into:
- Heart failure because of longstanding anemia
- Uncontrolled bleeding
- Severe infections
- Immunosuppressive therapy is associated with
- Relapse of the disease
- Induction of new cancers with prolonged use
- Serum sickness
- Avascular necrosis
- Opportunistic infections with suppression of the immune system
- Hematopoietic stem cell transplantation is associated with
- Graft Versus Host Disease (GVHD)
- Rejection of the graft